287 related articles for article (PubMed ID: 37237329)
21. Precancerous Cervical Lesion Among HIV-Positive Women in Sub-Saharan Africa: A Systematic Review and Meta-Analysis.
Weldegebreal F; Worku T
Cancer Control; 2019; 26(1):1073274819845872. PubMed ID: 31043067
[TBL] [Abstract][Full Text] [Related]
22. Mapping evidence on the distribution of human papillomavirus-related cancers in sub-Saharan Africa: scoping review protocol.
Lekoane BKM; Mashamba-Thompson TP; Ginindza TG
Syst Rev; 2017 Nov; 6(1):229. PubMed ID: 29149907
[TBL] [Abstract][Full Text] [Related]
23. Reflection: burden of cervical cancer in Sub-Saharan Africa and progress with HPV vaccination.
Ngcobo N; Jaca A; Iwu-Jaja CJ; Mavundza E
Curr Opin Immunol; 2021 Aug; 71():21-26. PubMed ID: 33857884
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain.
Linertová R; Guirado-Fuentes C; Mar-Medina J; Teljeur C
Hum Vaccin Immunother; 2022 Nov; 18(6):2127983. PubMed ID: 36347243
[TBL] [Abstract][Full Text] [Related]
25. Lessons learnt during the national introduction of human papillomavirus (HPV) vaccination programmes in 6 African countries: Stakeholders' perspectives.
Abdullahi LH; Hussey GD; Wiysonge CS; Kagina BM
S Afr Med J; 2020 May; 110(6):525-531. PubMed ID: 32880566
[TBL] [Abstract][Full Text] [Related]
26. Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease.
Mboumba Bouassa RS; Prazuck T; Lethu T; Jenabian MA; Meye JF; Bélec L
Expert Rev Anti Infect Ther; 2017 Jun; 15(6):613-627. PubMed ID: 28440679
[TBL] [Abstract][Full Text] [Related]
27. Gender neutral HPV vaccination programs: Reconsidering policies to expand cancer prevention globally.
Dykens JA; Peterson CE; Holt HK; Harper DM
Front Public Health; 2023; 11():1067299. PubMed ID: 36895694
[TBL] [Abstract][Full Text] [Related]
28. A systematic review of the barriers to implementing human papillomavirus vaccination programs in low- and middle-income countries in the Asia-Pacific.
Ver AT; Notarte KI; Velasco JV; Buac KM; Nazareno J; Lozañes JA; Antonio D; Bacorro W
Asia Pac J Clin Oncol; 2021 Dec; 17(6):530-545. PubMed ID: 33636046
[TBL] [Abstract][Full Text] [Related]
29. Cervical cancer in Ethiopia: a review of the literature.
Derbie A; Mekonnen D; Nibret E; Misgan E; Maier M; Woldeamanuel Y; Abebe T
Cancer Causes Control; 2023 Jan; 34(1):1-11. PubMed ID: 36242682
[TBL] [Abstract][Full Text] [Related]
30. Prevention of Cervical Cancer in Sub-Saharan Africa: The Advantages and Challenges of HPV Vaccination.
Black E; Richmond R
Vaccines (Basel); 2018 Sep; 6(3):. PubMed ID: 30205561
[TBL] [Abstract][Full Text] [Related]
31. Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa.
Tan N; Sharma M; Winer R; Galloway D; Rees H; Barnabas RV
Vaccine; 2018 Aug; 36(32 Pt A):4830-4836. PubMed ID: 29891348
[TBL] [Abstract][Full Text] [Related]
32. Using an Implementation Research Framework to Identify Potential Facilitators and Barriers of an Intervention to Increase HPV Vaccine Uptake.
Selove R; Foster M; Mack R; Sanderson M; Hull PC
J Public Health Manag Pract; 2017; 23(3):e1-e9. PubMed ID: 27902559
[TBL] [Abstract][Full Text] [Related]
33. Adherence barriers and interventions to improve ART adherence in Sub-Saharan African countries: A systematic review protocol.
Buh A; Deonandan R; Gomes J; Krentel A; Oladimeji O; Yaya S
PLoS One; 2022; 17(6):e0269252. PubMed ID: 35704636
[TBL] [Abstract][Full Text] [Related]
34. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Canfell K; Kim JJ; Brisson M; Keane A; Simms KT; Caruana M; Burger EA; Martin D; Nguyen DTN; Bénard É; Sy S; Regan C; Drolet M; Gingras G; Laprise JF; Torode J; Smith MA; Fidarova E; Trapani D; Bray F; Ilbawi A; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):591-603. PubMed ID: 32007142
[TBL] [Abstract][Full Text] [Related]
35. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
[TBL] [Abstract][Full Text] [Related]
36. Distribution of high- and low-risk human papillomavirus genotypes and their prophylactic vaccination coverage among West African women: systematic review.
Ouedraogo RA; Kande A; Nadembega WMC; Ouermi D; Zohoncon TM; Djigma FW; Ouedraogo CMR; Lompo OM; Simpore J
J Egypt Natl Canc Inst; 2023 Dec; 35(1):39. PubMed ID: 38060078
[TBL] [Abstract][Full Text] [Related]
37. Mapping Evidence on Management of Cervical Cancer in Sub-Saharan Africa: Scoping Review.
Zibako P; Hlongwa M; Tsikai N; Manyame S; Ginindza TG
Int J Environ Res Public Health; 2022 Jul; 19(15):. PubMed ID: 35954564
[TBL] [Abstract][Full Text] [Related]
38. Human Papillomavirus Vaccination in South Africa: Programmatic Challenges and Opportunities for Integration With Other Adolescent Health Services?
Amponsah-Dacosta E; Blose N; Nkwinika VV; Chepkurui V
Front Public Health; 2022; 10():799984. PubMed ID: 35174123
[TBL] [Abstract][Full Text] [Related]
39. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.
Hutubessy R; Levin A; Wang S; Morgan W; Ally M; John T; Broutet N
BMC Med; 2012 Nov; 10():136. PubMed ID: 23146319
[TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus distribution in invasive cervical carcinoma in sub-Saharan Africa: could HIV explain the differences?
Ndiaye C; Alemany L; Ndiaye N; Kamaté B; Diop Y; Odida M; Banjo K; Tous S; Klaustermeier JE; Clavero O; Castellsagué X; Bosch FX; Trottier H; de Sanjosé S
Trop Med Int Health; 2012 Dec; 17(12):1432-40. PubMed ID: 23107344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
